BWX TechnologiesBWXT

The company earned $1.07 per share last quarter, slightly better than the $1.04 analysts expected. Revenue reached about 902 million dollars, driven by growth in its commercial nuclear operations. Management also raised its full-year profit and cash flow targets, signaling that its core work building nuclear reactors for the Navy and power plants remains on track.

In a major shift, the company is selling its medical business for up to 800 million dollars. This unit makes isotopes used in medical imaging and treatments, but it required heavy spending to scale. Selling it allows the company to focus entirely on its nuclear engineering roots while using the cash to pay down debt or invest in its defense and commercial power segments.

See the full quarter, and how our tracked metrics did

Source: 8-K filing

Key highlights

• Commercial nuclear power surging: The commercial division revenue grew 72% to $302.5 million because of high demand for reactor components and services. This growth is helping the company become less reliant on government contracts, which only grew 2% this quarter.
• Full year outlook raised: Management raised its 2026 profit guidance to a range of $4.70 to $4.80 per share, up from the previous high of $4.75. This suggests the company expects its strong start to the year to continue through its recent acquisition and steady nuclear demand.
• Medical business sale announced: The company is selling its medical division, which contributed to the $302.5 million in commercial sales this quarter, to focus entirely on its core nuclear power and defense markets. Management believes exiting this line of business will free up more resources for heavy nuclear manufacturing.
• Free cash flow dip: Free cash flow, which is the cash a company has left after paying for its operations and equipment, fell 9% to $115 million. This decline happened because the company spent $41.4 million on new growth projects, mainly to expand its commercial factories.
• Record backlog visibility: The total backlog of future work grew to $8.39 billion compared to $6.01 billion a year ago. This provides years of predictable work for the company, especially in government nuclear propulsion where the backlog now stands at $6.79 billion.

Our take: This was a standout quarter that showed the company is successfully pivoting toward the booming commercial nuclear market. The 72% jump in commercial revenue and the decision to sell the medical business both signal a clear, profitable focus on core nuclear infrastructure. It strengthens the long term case for the business as a leader in clean energy transition.